|Other Names||E3 ubiquitin-protein ligase RNF43, 632-, RING finger protein 43, RNF43|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP13204b was selected from the C-term region of RNF43. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||E3 ubiquitin-protein ligase that acts as a negative regulator of the Wnt signaling pathway by mediating the ubiquitination, endocytosis and subsequent degradation of Wnt receptor complex components Frizzled. Acts on both canonical and non-canonical Wnt signaling pathway. Acts as a tumor suppressor in the intestinal stem cell zone by inhibiting the Wnt signaling pathway, thereby resticting the size of the intestinal stem cell zone.|
|Cellular Location||Cell membrane; Single-pass type I membrane protein. Endoplasmic reticulum membrane; Single-pass type I membrane protein. Nucleus envelope. Note=According to a report, may be secreted.|
|Tissue Location||Expressed in fetal kidney, fetal lung, in colon cancer tissues, hepatocellular carcinomas and lung adenocarcinomas. Overexpressed in colorectal cancer cell lines|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
RNF43 is a HAP95 (AKAP8L; MIM 609475) binding ubiquitinligase that promotes cell growth and is upregulated in colon cancer(Yagyu et al., 2004 [PubMed 15492824]; Sugiura et al., 2008 [PubMed18313049]).
Low, S.K., et al. PLoS ONE 5 (7), E11824 (2010) :Sugiura, T., et al. Exp. Cell Res. 314(7):1519-1528(2008)Uchida, N., et al. Clin. Cancer Res. 10(24):8577-8586(2004)Yagyu, R., et al. Int. J. Oncol. 25(5):1343-1348(2004)
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.